Many investors and some analysts welcomed the move, seeing it as a sign that Summit's co-CEOs expect the company's shares to ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Q1 2025 Management View CEO Jonathan Stanner discussed Q1 2025 results, highlighting a 1.5% RevPAR growth in the same-store portfolio, driven by a mix of rate and occupancy improvements. He ...

Growth equity firm Summit Partners invested $55 million in Instrumentl, a startup that helps nonprofits and universities find ...

“Many of our Summit community members are building and running large high-profile companies, managing teams, and are surrounded by people and things to do. But our business leaders often feel ...

Summit, a leading superregional provider of workers' compensation insurance services, is pleased to announce significant ...

Discover Summit Therapeutics' Q1 2025 milestones, including ivonescimab progress, the global HARMONi trial, and strategic oncology collaborations.